Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sutro Biopharma, Inc. - Common Stock (NQ: STRO )

1.890 -0.080 (-4.06%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 808,808
Open 1.980
Bid (Size) 1.840 (10)
Ask (Size) 1.900 (6)
Prev. Close 1.970
Today's Range 1.830 - 2.005
52wk Range 1.700 - 5.880
Shares Outstanding 60,416,916
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Outlook: Sutro Biopharma Through The Eyes Of 6 Analysts
Via Benzinga
A Glimpse Into The Expert Outlook On Sutro Biopharma Through 5 Analysts
Via Benzinga

Performance

YTD
-58.64%
-58.64%
1 Month
-28.68%
-28.68%
3 Month
-45.38%
-45.38%
6 Month
-38.03%
-38.03%
1 Year
-55.94%
-55.94%

More News

Read More
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Lyft Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Peeling Back The Layers: Exploring Sutro Biopharma Through Analyst Insights
Via Benzinga
Analyst Expectations For Sutro Biopharma's Future
Via Benzinga
Expert Outlook: Sutro Biopharma Through The Eyes Of 10 Analysts
Via Benzinga
What's Going On With Sutro Biopharma (STRO) Stock?
Via Benzinga
STRO Stock Earnings: Sutro Biopharma Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
Via Benzinga
Navigating 4 Analyst Ratings For Sutro Biopharma
Via Benzinga
Expert Ratings for Sutro Biopharma
Via Benzinga
Where Sutro Biopharma Stands With Analysts
Via Benzinga
STRO Stock Earnings: Sutro Biopharma Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
Via Benzinga
5 Analysts Have This to Say About Sutro Biopharma
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
STRO Stock Earnings: Sutro Biopharma Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
From Vaxcyte, Inc.
Via GlobeNewswire
Sutro Biopharma's Lead Ovarian Cancer Candidate Is A Game Changer, Analyst Sees Huge Upside
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.